{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:55:52Z","timestamp":1791276952180,"version":"4.1.0"},"reference-count":31,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2016,6,3]],"date-time":"2016-06-03T00:00:00Z","timestamp":1464912000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2016,6,3]],"date-time":"2016-06-03T00:00:00Z","timestamp":1464912000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is limited information about active tuberculosis (TB) occurring in psoriasis patients treated with Tumor necrosis factor (TNF) antagonists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe the clinical characteristics of TB in psoriasis patients treated with TNF antagonists.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Nationwide retrospective study of psoriasis patients having experienced TB. Cases of TB were collected via three methods: search in the national pharmacosurveillance database, questionnaire to members of the French psoriasis research group, the college of French dermatology professors. We collected demographic data, TNF antagonist used, screening for latent tuberculosis infection, median time between TNF antagonists introduction and first symptoms, tests used for diagnosing TB infection, clinical features of tuberculosis and outcome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight centres reported 12 cases of TB between 2006 and 2014. They were nine men and three women with mean age of 49 years. All patients had adequate screening for latent tuberculosis. Three patients had stayed in endemic areas, three reported contact with a patient with TB. Tuberculosis presentation was extrapulmonary in 10 patients. Seven patients were treated with infliximab, four with adalimumab and one with certolizumab. The median time between TNF antagonist introduction and first symptoms of tuberculosis was 23.4 weeks (2\u2013176). Six of the 12 patients had a positive direct examination and\/or positive culture for Mycobacterium tuberculosis. Histological samples of affected organs taken from seven patients showed granulomatous inflammation in six, with caseating necrosis in five. Two of the 12 patients died of disseminated TB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study shows tuberculosis in patients treated with TNF antagonists still occurs despite adherence to tuberculosis prevention guidelines. Prophylactic measures do not fully prevent the occurrence of tuberculosis. Rapid initiation of effective anti\u2010tuberculosis treatment is important even in patients with negative mycobacteriological examination presenting with suggestive symptoms and organ involvement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.13633","type":"journal-article","created":{"date-parts":[[2016,6,3]],"date-time":"2016-06-03T03:43:22Z","timestamp":1464925402000},"page":"1336-1341","source":"Crossref","is-referenced-by-count":17,"title":["Active tuberculosis in psoriasis patients treated with\n                    <scp>TNF<\/scp>\n                    antagonists: a French nationwide retrospective study"],"prefix":"10.1111","volume":"30","author":[{"given":"E.","family":"Guinard","sequence":"first","affiliation":[{"name":"Service de dermatologie CHU Toulouse Larrey Universit\u00e9 Paul Sabatier Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bulai Livideanu","sequence":"additional","affiliation":[{"name":"Service de dermatologie CHU Toulouse Larrey Universit\u00e9 Paul Sabatier Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Barth\u00e9l\u00e9my","sequence":"additional","affiliation":[{"name":"Service de dermatologie CH Auxerre Auxerre France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Viguier","sequence":"additional","affiliation":[{"name":"Service de dermatologie CHU Saint Louis Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Reguiai","sequence":"additional","affiliation":[{"name":"Service de dermatologie CHU de Reims Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Richard","sequence":"additional","affiliation":[{"name":"Service de dermatologie H\u00f4pital Timone Assistance publique des H\u00f4pitaux de Marseille Universit\u00e9 Aix Marseille Marseille France"},{"name":"UMR 911 INSERM CRO2, \u201cCentre de recherche en oncologie biologique et onco phamacologie Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Jullien","sequence":"additional","affiliation":[{"name":"Service de dermatologie CHU Lyon Universit\u00e9 de Lyon Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Beneton","sequence":"additional","affiliation":[{"name":"Service de dermatologie CH du Mans Le Mans France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bara","sequence":"additional","affiliation":[{"name":"Service de dermatologie CH du Mans Le Mans France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Vabres","sequence":"additional","affiliation":[{"name":"Service de dermatologie CHU Dijon Dijon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Grandvuillemin","sequence":"additional","affiliation":[{"name":"Centre r\u00e9gional pharmacovigilance CHU Dijon Dijon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Marguery","sequence":"additional","affiliation":[{"name":"Service de dermatologie CHU Toulouse Larrey Universit\u00e9 Paul Sabatier Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Amelot","sequence":"additional","affiliation":[{"name":"Service de dermatologie CHU Toulouse Larrey Universit\u00e9 Paul Sabatier Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.P.","family":"Konstantinou","sequence":"additional","affiliation":[{"name":"Service de dermatologie CHU Toulouse Larrey Universit\u00e9 Paul Sabatier Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Bagheri","sequence":"additional","affiliation":[{"name":"Service de pharmacologie m\u00e9dicale et clinique CHU Toulouse Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Paul","sequence":"additional","affiliation":[{"name":"Service de dermatologie CHU Toulouse Larrey Universit\u00e9 Paul Sabatier Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the French Psoriasis Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,6,3]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2013.03.005"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11137"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.118935"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.24632"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21978"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rhum.2010.09.018"},{"key":"e_1_2_6_9_1","unstructured":"Afssaps.Pr\u00e9vention et prise en charge des tuberculoses survenant sous anti\u2010TNFa. [WWW document]2005. URLhttp:\/\/www.ansm.sante.fr\/content\/download\/12022\/143647\/version\/2\/file\/reco.pdf(last accessed: April 20 2016)."},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2005.046797"},{"key":"e_1_2_6_11_1","first-page":"219","article-title":"National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients treated with systemic and biologic agents","volume":"59","author":"Dohert SD","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmr.2011.07.011"},{"key":"e_1_2_6_13_1","unstructured":"HAS.Test de d\u00e9tection de la production d'IFN \u03b3 pour le diagnostic des infections tuberculeuses. [WWW document]2006. URLhttp:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/synthese_detection_de_linterferon-gamma.pdf(last accessed: April 20 2016)."},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rhum.2010.09.005"},{"key":"e_1_2_6_15_1","first-page":"37","article-title":"Le remplacement de l'intradermor\u00e9action (IDR) \u00e0 la tuberculine par les tests sanguins sp\u00e9cifiques permet de diviser par deux la fr\u00e9quence de la tuberculose (TB) latente. R\u00e9sultats de l'\u00e9tude ETAT chez 369 patients avant mise sous anti\u2010TNF","volume":"77","author":"Mariette X","year":"2010","journal-title":"Rev Rhum"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21043"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.072967"},{"key":"e_1_2_6_18_1","first-page":"39","article-title":"Section IV: long\u2010term management of the transplant recipient IV.7.2. Late infections. Tuberculosis","volume":"17","author":"European best practice guidelines for renal transplantation (expert group)","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0761-8425(08)75089-7"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1191\/0961203303lu529xx"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199705150-00015"},{"key":"e_1_2_6_22_1","first-page":"1","article-title":"Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendation","volume":"47","author":"Centers for Disease Control and Prevention","year":"1998","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_6_23_1","first-page":"399","article-title":"Comparative evaluation of 113 cases with severe and mild forms of extrapulmonary tuberculosis","volume":"42","author":"Turun\u00e7 T","year":"2008","journal-title":"Mikrobiyol Bul"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2009.05.012"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00034-13"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir410"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129792"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2011.09.008"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.070789"},{"key":"e_1_2_6_30_1","first-page":"64","article-title":"Impact of screening for latent TB prior to initiating anti\u2010TNF therapy","author":"Perez J","year":"2005","journal-title":"[Abstract] Ann Rheum Dis"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.12628"},{"key":"e_1_2_6_32_1","unstructured":"HAS.Commission de la transparence. [WWW document]2008. URLhttp:\/\/www.has-sante.fr\/portail\/upload\/docs\/application\/pdf\/2008-06\/ct-5381_humira_.pdf(last accessed: April 20 2016)."}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13633","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.13633","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.13633","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.13633","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.13633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:47:17Z","timestamp":1791276437000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.13633"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,3]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1111\/jdv.13633"],"URL":"https:\/\/doi.org\/10.1111\/jdv.13633","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,3]]}}}